EGFR and non-small cell lung carcinoma: This research aimed to systematically compare the cost-effectiveness of two treatment strategies: sintilimab plus IBI305 and chemotherapy, and sintilimab plus chemotherapy versus chemotherapy alone, in Chinese patients with EGFR-mutated NSCLC who had progressed on EGFR TKI treatment.